צמיחת מכירות משנה לשנה ב-12 החודשים האחרונים: Entera Bio (ENTX)

Entera Bio Ltd. (ENTX) transforms injectable drugs into tablets, simplifying osteoporosis therapy through oral protein delivery. The TTM annual revenue trend captures operational shifts, where the -99.80 mark reflects the current state of the metric. Stable leadership under Daniel Levkovich and the non-cyclical nature of biotech development provide the business with high macro-resilience, which remains dependent on FDA decisions.
Entera Bio Ltd (ENTX) - פילוחי מדדים ודוחות פיננסיים

Year-over-year (TTM) sales growth measures revenue dynamics over the last 12 months relative to the same period last year. This indicator determines the sustainability of business expansion by neutralizing short-term volatility. For Entera Bio Ltd. (ENTX), the development of this metric reflects the commercial success of transitioning from injections to oral drug formulations. By analyzing the revenue trend over four quarters compared to the previous year, an investor assesses the pace of market capture within osteoporosis therapy. Stable growth confirms the scalability of the innovative macromolecule delivery technology.